Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials
Authors:
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Roche
- Gilead Sciences
- Bristol-Myers Squibb
This publication has 25 references indexed in Scilit:
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB StudyJournal of Clinical Oncology, 2012
- Trastuzumab containing regimens for early breast cancerCochrane Database of Systematic Reviews, 2012
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialThe Lancet, 2012
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancerCancer Treatment Reviews, 2010
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortThe Lancet, 2010
- Lapatinib plus letrozole for postmenopausal patients with advanced HER2+/HR+breast cancerExpert Review of Anticancer Therapy, 2009
- Primary systemic therapy for operable breast cancer: A review of clinical trials and perspectivesCancer Letters, 2007
- Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast CancerJournal of Clinical Oncology, 2005